Buprenorphine/granisetron controlled release - Camurus/Braeburn

Drug Profile

Buprenorphine/granisetron controlled release - Camurus/Braeburn

Alternative Names: BB0417; CAM 2058

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Camurus
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Cyclopropanes; Indazoles; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Postoperative nausea and vomiting; Postoperative pain

Most Recent Events

  • 28 Nov 2016 Camurus files an clinical trial application in Sweden for Postoperative pain and Postoperative nausea and vomiting
  • 24 Oct 2016 Buprenorphine/granisetron licensed to Braeburn Pharmaceuticals in North America
  • 24 Oct 2016 Preclinical trials in Postoperative pain and Postoperative nausea and vomiting (Prevention) in Sweden (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top